A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area

BACKGROUND: H1/IC31® is a tuberculosis (TB) subunit vaccine candidate consisting of the fusion protein of Ag85B and ESAT-6 (H1) formulated with the IC31® adjuvant. Previous trials have reported on the H1/IC31® vaccine in M. tuberculosis (Mtb)-naïve, BCG-vaccinated and previously Mtb-infected individ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussein, Jemal, Zewdie, Martha, Yamuah, Lawrence, Bedru, Ahmed, Abebe, Markos, Dagnew, Alemnew F., Chanyalew, Menberework, Yohannes, Asfawesen G., Ahmed, Jemal, Engers, Howard, Doherty, T. Mark, Bang, Peter, Kromann, Ingrid, Hoff, Søren T., Aseffa, Abraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764015/
https://www.ncbi.nlm.nih.gov/pubmed/29321075
http://dx.doi.org/10.1186/s13063-017-2354-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764015/
https://www.ncbi.nlm.nih.gov/pubmed/29321075
http://dx.doi.org/10.1186/s13063-017-2354-0

Ejemplares similares